Karyopharm Therapeutics Inc. (KPTI) return on equity (ROE)

Return on equity · fiscal 2020
-388.3%

Karyopharm Therapeutics Inc. (KPTI) earned a return on equity of -388.3% in fiscal 2020 (the year ended December 31, 2020). That is 12.7 percentage points higher than the -401.0% of fiscal 2019. Figures as of 18 Nov 2026, 01:06 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2020
-388.3%
Change on fiscal 2019
+12.7 pts
Highest on record
-21.9%fiscal 2013
Lowest on record
-401.0%fiscal 2019
Fiscal years on record
82013–2020

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Karyopharm Therapeutics Inc. return on equity (ROE), in more detail

Across the 8 fiscal years on record (2013–2020), the highest was -21.9% in fiscal 2013 and the lowest -401.0% in fiscal 2019. The fiscal 2020 figure is higher than in 14% of the 7 earlier fiscal years on record, whose median is -67.5%.

History · 8 fiscal years

Return on equity by fiscal year

Karyopharm Therapeutics Inc. return on equity (ROE), year by year

Karyopharm Therapeutics Inc. (KPTI) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2020-388.3% 12.7 pts up
2019-401.0% 303.6 pts down
2018-97.4% 2.2 pts up
2017-99.6% 32.1 pts down
2016-67.5% 8.0 pts down
2015-59.6% 22.9 pts down
2014-36.6% 14.7 pts down
2013-21.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on KPTI

Karyopharm Therapeutics Inc., figure by figure

Karyopharm Therapeutics Inc. (KPTI) overview: price, valuation and scorecard

Karyopharm Therapeutics Inc. return on equity (ROE): questions and answers

What is Karyopharm Therapeutics Inc.'s return on equity?

Karyopharm Therapeutics Inc. (KPTI) earned a return on equity of -388.3% in fiscal 2020 (the year ended December 31, 2020). That is 12.7 percentage points higher than the -401.0% of fiscal 2019.

Is Karyopharm Therapeutics Inc.'s return on equity high or low compared with its own history?

The fiscal 2020 figure is higher than in 14% of the 7 earlier fiscal years on record, whose median is -67.5%.

What are the highest and lowest return on equity figures on record for Karyopharm Therapeutics Inc.?

Across the 8 fiscal years on record (2013–2020), the highest was -21.9% in fiscal 2013 and the lowest -401.0% in fiscal 2019.

How is Karyopharm Therapeutics Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Karyopharm Therapeutics Inc. (KPTI) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/KPTI/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.